380 related articles for article (PubMed ID: 31647392)
1. Identification of potential inhibitors for HCV NS5b of genotype 4a by combining dynamic simulation, protein-ligand interaction fingerprint, 3D pharmacophore, docking and 3D QSAR.
El-Hassab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2020 Sep; 38(15):4521-4535. PubMed ID: 31647392
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
[TBL] [Abstract][Full Text] [Related]
3. Multiple e-pharmacophore modeling, 3D-QSAR, and high-throughput virtual screening of hepatitis C virus NS5B polymerase inhibitors.
Therese PJ; Manvar D; Kondepudi S; Battu MB; Sriram D; Basu A; Yogeeswari P; Kaushik-Basu N
J Chem Inf Model; 2014 Feb; 54(2):539-52. PubMed ID: 24460140
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors.
Patel PD; Patel MR; Kaushik-Basu N; Talele TT
J Chem Inf Model; 2008 Jan; 48(1):42-55. PubMed ID: 18076152
[TBL] [Abstract][Full Text] [Related]
5. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
6. Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase.
Wang Z; Chen Z; Li J; Huang J; Zheng C; Liu JP
J Biomol Struct Dyn; 2020 Mar; 38(4):1071-1082. PubMed ID: 30915896
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking.
Wei Y; Li J; Qing J; Huang M; Wu M; Gao F; Li D; Hong Z; Kong L; Huang W; Lin J
PLoS One; 2016; 11(2):e0148181. PubMed ID: 26845440
[TBL] [Abstract][Full Text] [Related]
8. Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening.
Vrontaki E; Melagraki G; Mavromoustakos T; Afantitis A
J Enzyme Inhib Med Chem; 2016; 31(1):38-52. PubMed ID: 26060939
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential tumour-associated carbonic anhydrase isozyme IX inhibitors: atom-based 3D-QSAR modelling, pharmacophore-based virtual screening and molecular docking studies.
Kumar A; Rathi E; Kini SG
J Biomol Struct Dyn; 2020 Apr; 38(7):2156-2170. PubMed ID: 31179854
[TBL] [Abstract][Full Text] [Related]
10. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
Elfiky AA
Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
Shah BM; Modi P; Trivedi P
J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
[TBL] [Abstract][Full Text] [Related]
12. Insight into the structural requirements of benzothiadiazine scaffold-based derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics.
Zhang HX; Li Y; Wang X; Xiao ZT; Wang YH
Curr Med Chem; 2011; 18(26):4019-28. PubMed ID: 21824089
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Luo PH; Zhang XR; Huang L; Yuan L; Zhou XZ; Gao X; Li LS
J Recept Signal Transduct Res; 2017 Oct; 37(5):481-492. PubMed ID: 28758854
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
[TBL] [Abstract][Full Text] [Related]
15. Discovery of hit molecules targeting allosteric site of hepatitis C virus NS5B polymerase.
Polamreddy P; Vishwakarma V; Arumugam P; Bheemanati R; Esram P; Mahto MK; Kacker P
J Biomol Struct Dyn; 2020 Mar; 38(5):1448-1466. PubMed ID: 31007134
[TBL] [Abstract][Full Text] [Related]
16. Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches.
Jana S; Singh SK
J Biomol Struct Dyn; 2019 Mar; 37(4):944-965. PubMed ID: 29475408
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors.
Poonia P; Sharma M; Jha P; Chopra M
Mol Divers; 2023 Oct; 27(5):2053-2071. PubMed ID: 36214962
[TBL] [Abstract][Full Text] [Related]
18. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR, Virtual Screening, Docking and Design of Dual PI3K/mTOR Inhibitors with Enhanced Antiproliferative Activity.
Oluić J; Nikolic K; Vucicevic J; Gagic Z; Filipic S; Agbaba D
Comb Chem High Throughput Screen; 2017 Aug; 20(4):292-303. PubMed ID: 28460621
[TBL] [Abstract][Full Text] [Related]
20. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
